



Food and Drugs Authority

Head Office
P. O. Box CT 2783,
Cantonments, Accra - Ghana
Tel: (+233-302)233200, 235100
Fax: (+233-302)229794, 225502
Email: fda@fdaghana.gov.gh

FDA/SMC/SMD/VGU/18/0395

3rd December 2018

Dear Healthcare Professional,

FOLLOW-UP: SUSPENSION OF MARKETING AUTHORIZATION FOR CODEINE-CONTAINING COUGH SYRUPS

This is a follow up to the Food and Drugs Authority's Dear Healthcare Professional (DHCP) letter reference number FDA/SMC/SMD/VGU/18/0293 and dated 17th July 2018¹ regarding the suspension of marketing authorization for codeine-containing cough syrups.

The FDA wishes to inform you that the Hon. Minister of Health on 22nd August 2018 issued an Executive Instrument, E.I 167 on the suspension, registration, importation and the manufacture of codeine- containing cough syrups. The E.I can be accessed on the FDA website on the link below:

<https://fdaghana.gov.gh/images/stories/pdfs/News%20&%20Events/EXECUTIVE%20INSTRUMENT%20167.pdf>

In view of this suspension the FDA has taken stock of available CCS up to manufacturing and warehouse levels and monitoring the use of the product.

The FDA has given a phase-out period for the use of the current stock and the underlisted should be strictly adhered to during the period.

- CCS should be prescribed only when necessary.
- CCS should be dispensed only on valid prescription and record of the prescription kept at the pharmacy.

As an alternative for codeine, the FDA has registered a number of products containing dextromethorphan which are recommended for the management of symptoms of dry cough in adults.

¹ <https://fdaghana.gov.gh/images/stories/pdfs/Dear%20Helthcare%20Prof/2018/18-293-SUSPENSION%20OF%20MAH%20FOR%20CCCS-SIGNED0001.pdf>

